MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

Merus N.V. (MRUS) shares surged nearly 30% over the past three months following encouraging interim Phase II results for its petosemtamab in combination with Merck's Keytruda as a first-line treatment for head and neck squamous cell carcinoma (HNSCC). The combo therapy demonstrated a 63% overall response rate and a median progression-free survival of nine months, showing superior efficacy compared to Keytruda monotherapy with a manageable safety profile. This data positions the combination with significant potential to become a new standard of care, with registrational Phase III studies currently underway and top-line readouts anticipated in 2026.

Analysis

Merus N.V. (MRUS) has demonstrated significant clinical progress, fueling a 29.9% stock appreciation over the last three months. The primary driver is the encouraging interim data from its Phase II study of petosemtamab in combination with Merck’s Keytruda for first-line head and neck squamous cell carcinoma (HNSCC). The combination therapy achieved a compelling 63% overall response rate (ORR) and a median progression-free survival (PFS) of nine months, which the report notes shows superior efficacy compared to Keytruda monotherapy. The robust response was observed across varying PD-L1 expression levels, and the 79% overall survival rate at 12 months is a strong early signal. Critically, the safety profile was manageable with no significant overlapping toxicities, a key consideration for combination treatments. This positive data de-risks the asset and positions the therapy as a potential new standard of care. The next major catalysts are the top-line interim readouts from two registrational Phase III studies, expected in 2026, which will be crucial for ultimate validation and regulatory submission.

Key Decisions for Investors

• The strong Phase II results significantly de-risk petosemtamab, and investors with a high risk tolerance and a long-term outlook could view the recent rally as fundamentally supported, warranting a bullish stance.
• The investment thesis is now heavily dependent on the successful outcome of the pivotal Phase III trials, with the 2026 data readout being the most critical future catalyst to monitor.
• Investors should consider the strategic partnership with Merck, as the combination with the blockbuster drug Keytruda is a core value driver, although the potential for petosemtamab to outperform Keytruda monotherapy also presents a significant competitive advantage.